Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.PolyTherics has purchased Warwick Effect Polymers (WEP), a provider of specialty biopolymers for the modification of biological products.
Subscribe to our email newsletter
WEP has developed two proprietary biopolymer technologies, PolyPEG and GlycoPol.
WEP has agreements with global pharmaceutical and biotechnology companies for the evaluation of PolyPEG or GlycoPol and the company expects to announce licensing deals for these technologies in 2012.
PolyPEG is a low viscosity comb polymer for extending the duration of action of biopharmaceuticals and which is especially applicable to high concentration protein products.
GlycoPol, a glycopolymer, targets the delivery of therapeutic agents, including RNAi and aptamer molecules, to specific glycan receptors on cells and has the potential to facilitate their intracellular uptake.
PolyTherics CEO John Burt said with the acquisition of WEP, PolyTherics now has broader technology capabilities for the pharmaceutical and biotechnology company partners that the two companies have separately served.